Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors, and Glycosylation and Glycoproteins Research.
A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization.
Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage.
Molecular Characterization and Clinical Relevance of <i>MGMT</i>‐Silenced Pancreatic Cancer
Is tumour sequencing effective for the identification of germline <i>BRCA1/2</i> pathogenic variant carriers?
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials.
Is tumour sequencing effective for the identification of germline <i>BRCA1/2</i> pathogenic variant carriers?
Data from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Data from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Table S2 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Table S1 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Table S1 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S4 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S2 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S2 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S3 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S3 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Table S2 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S1 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S1 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Supplementary Figure S4 from Negative Hyperselection of Patients with HER2<sup>+</sup> and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis